The emerging role of FTY720 (Fingolimod) in cancer treatment

Oncotarget

Volumn 7, Issue 17, 2016, Pages 23106-23127

  White, Christopher ^a   Alshaker, Heba ^b,c   Cooper, Colin ^c   Winkler, Matthias ^a   Pchejetski, Dmitri ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PETRA   (Jordan)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Cancer; Fingolimod; FTY720; Sphingolipid; Sphingosine kinase

Indexed keywords

AUTOTAXIN; FINGOLIMOD; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; IMMUNOSUPPRESSIVE AGENT;

APOPTOSIS; ARTICLE; AUTOPHAGY; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL MIGRATION; CELL TRANSPORT; COLON CANCER; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; GLIOMA; HUMAN; IN VITRO STUDY; INFLAMMATION; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; LYMPHOMA; MOLECULAR THERAPY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPHINGOLIPID METABOLISM; STOMACH CANCER; TUMOR VASCULARIZATION; ANIMAL; DRUG EFFECTS; NEOPLASM; PROGNOSIS;

ANIMALS; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84966692498     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7145     Document Type: Article

References (250)

1. Morad SA and Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer. 2013; 13(1):51-65.
2. Proia RL and Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015; 125(4):1379-1387.
3. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S and Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996; 381(6585):800-803.
4. Hannun YA and Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008; 9(2):139-150.
5. Takabe K, Paugh SW, Milstien S and Spiegel S. "Insideout" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008; 60(2):181-195.
6. Newton J, Lima S, Maceyka M and Spiegel S. Revisiting the sphingolipid rheostat: Evolving concepts in cancer therapy. Exp Cell Res. 2015; 333(2):195-200.
7. Taha TA, Hannun YA and Obeid LM. Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol. 2006; 39(2):113-131.
8. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci. 2011; 36:97-107.
9. Pyne S, Lee SC, Long J and Pyne NJ. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal. 2009; 21(1):14-21.
10. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S and Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem. 2003; 278(47):46832-46839.
11. Pitson SM, Moretti PA, Zebol JR, Xia P, Gamble JR, Vadas MA, D'Andrea RJ and Wattenberg BW. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J Biol Chem. 2000; 275(43):33945-33950.
12. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA and Wattenberg BW. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. Embo J. 2003; 22(20):5491-5500.
13. Tani M, Ito M and Igarashi Y. Ceramide/sphingosine/ sphingosine 1-phosphate metabolism on the cell surface and in the extracellular space. Cell Signal. 2007; 19(2):229-237.
14. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S and Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. 2005; 25(24):11113-11121.
15. Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, Wattenberg BW and Vadas MA. Phosphorylationdependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med. 2005; 201(1):49-54.
16. Takabe K and Spiegel S. Export of sphingosine-1-phosphate and cancer progression. J Lipid Res. 2014; 55(9):1839-1846.
17. Payne SG, Milstien S and Spiegel S. Sphingosine-1-phosphate: dual messenger functions. FEBS Lett. 2002; 531(1):54-57.
18. Verzijl D, Peters SL and Alewijnse AE. Sphingosine-1-phosphate receptors: zooming in on ligand-induced intracellular trafficking and its functional implications. Mol Cells. 2010; 29(2):99-104.
19. Oo ML, Thangada S, Wu MT, Liu CH, Macdonald TL, Lynch KR, Lin CY and Hla T. Immunosuppressive and antiangiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007; 282(12):9082-9089.
20. Strub GM, Maceyka M, Hait NC, Milstien S and Spiegel S. Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol. 2010; 688:141-155.
21. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, Luo C, Marmorstein R, Kordula T, Milstien S and Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009; 325(5945):1254-1257.
22. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, Maceyka M, Jiang H, Luo C, Kordula T, Milstien S and Spiegel S. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010; 465(7301):1084-1088.
23. Beckham TH, Cheng JC, Marrison ST, Norris JS and Liu X. Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv Cancer Res. 2013; 117:1-36.
24. Johnson KR, Johnson KY, Crellin HG, Ogretmen B, Boylan AM, Harley RA and Obeid LM. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J Histochem Cytochem. 2005; 53(9):1159-1166.
25. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ and Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol. 2005; 64(8):695-705.
26. Bayerl MG, Bruggeman RD, Conroy EJ, Hengst JA, King TS, Jimenez M, Claxton DF and Yun JK. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma. 2008; 49(5):948-954.
27. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK and Smith CD. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003; 63(18):5962-5969.
28. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, Pyne S, Pyne NJ and Edwards J. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signalregulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. The American journal of pathology. 2010; 177(5):2205-2215.
29. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, Yuan J, Zheng YJ, Huang ZS and Li M. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res. 2008; 14(21):6996-7003.
30. Ruckhaberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grosch S, Geisslinger G, Holtrich U, Karn T and Kaufmann M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat. 2008; 112(1):41-52.
31. Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P and Cuvillier O. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer. 2010.
32. Li W, Yu CP, Xia JT, Zhang L, Weng GX, Zheng HQ, Kong QL, Hu LJ, Zeng MS, Zeng YX, Li M, Li J and Song LB. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res. 2009; 15(4):1393-1399.
33. Song L, Xiong H, Li M, Liao WT, Wang L and Wu J. Sphingosine kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NF-[kappa]B Pathway in Human Non-small Cell Lung Cancer. Clin Cancer Res. 2011; 17:1839-49.
34. Liu G, Zheng H, Zhang Z, Wu Z, Xiong H, Li J and Song L. Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy. BMC Cancer. 2010; 10:495.
35. Facchinetti MM, Gandini NA, Fermento ME, Sterin-Speziale NB, Ji Y, Patel V, Gutkind JS, Rivadulla MG and Curino AC. The Expression of Sphingosine Kinase-1 in Head and Neck Carcinoma. Cells Tissues Organs. 2010; 192:314-24.
36. Sinha UK, Schorn VJ, Hochstim C, Chinn SB, Zhu S and Masood R. Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition. Head Neck. 2011; 33:178-88.
37. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, D'Andrea RJ and Vadas MA. An oncogenic role of sphingosine kinase. Curr Biol. 2000; 10(23):1527-1530.
38. Loveridge C, Tonelli F, Leclercq T, Lim KG, Long JS, Berdyshev E, Tate RJ, Natarajan V, Pitson SM, Pyne NJ and Pyne S. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. The Journal of biological chemistry. 2010; 285(50):38841-38852.
39. Dayon A, Brizuela L, Martin C, Mazerolles C, Pirot N, Doumerc N, Nogueira L, Golzio M, Teissie J, Serre G, Rischmann P, Malavaud B and Cuvillier O. Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival. PLoS One. 2009; 4(11):e8048.
40. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B and Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005; 65(24):11667-11675.
41. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T and Cuvillier O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia. 2006; 20(1):95-102.
42. Leroux ME, Auzenne E, Evans R, Hail N, Jr., Spohn W, Ghosh SC, Farquhar D, McDonnell T and Klostergaard J. Sphingolipids and the sphingosine kinase inhibitor, SKI II, induce BCL-2-independent apoptosis in human prostatic adenocarcinoma cells. Prostate. 2007; 67(15):1699-1717.
43. Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y and Nozawa Y. High expression of sphingosine kinase 1 and S1P receptors in chemotherapyresistant prostate cancer PC3 cells and their camptothecininduced up-regulation. Biochem Biophys Res Commun. 2006; 342(4):1284-1290.
44. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissie J, Malavaud B, Waxman J and Cuvillier O. FTY720 (Fingolimod) Sensitizes Prostate Cancer Cells to Radiotherapy by Inhibition of Sphingosine Kinase-1. Cancer research. 2010; 70:8651-61.
45. Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R, Barbour SE, Milstien S and Spiegel S. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal. Faseb J. 2008; 22(8):2629-2638.
46. Bektas M, Jolly PS, Muller C, Eberle J, Spiegel S and Geilen CC. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene. 2005; 24(1):178-187.
47. Nava VE, Hobson JP, Murthy S, Milstien S and Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp Cell Res. 2002; 281(1):115-127.
48. Sukocheva OA, Wang L, Albanese N, Pitson SM, Vadas MA and Xia P. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol Endocrinol. 2003; 17(10):2002-2012.
49. Melendez AJ and Ibrahim FB. Antisense knockdown of sphingosine kinase 1 in human macrophages inhibits C5a receptor-dependent signal transduction, Ca2+ signals, enzyme release, cytokine production, and chemotaxis. J Immunol. 2004; 173(3):1596-1603.
50. Pettus BJ, Bielawski J, Porcelli AM, Reames DL, Johnson KR, Morrow J, Chalfant CE, Obeid LM and Hannun YA. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. Faseb J. 2003; 17(11):1411-1421.
51. Weigert A, Tzieply N, von Knethen A, Johann AM, Schmidt H, Geisslinger G and Brune B. Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate. Mol Biol Cell. 2007; 18(10):3810-3819.
52. Xie B, Shen J, Dong A, Rashid A, Stoller G and Campochiaro PA. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J Cell Physiol. 2009; 218(1):192-198.
53. Condeelis J and Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006; 124(2):263-266.
54. Karin M and Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005; 5(10):749-759.
55. Johann AM, Weigert A, Eberhardt W, Kuhn AM, Barra V, von Knethen A, Pfeilschifter JM and Brune B. Apoptotic cell-derived sphingosine-1-phosphate promotes HuRdependent cyclooxygenase-2 mRNA stabilization and protein expression. J Immunol. 2008; 180(2):1239-1248.
56. Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, Khew-Goodall Y, Bert AG, Barter PJ and Vadas MA. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci U S A. 1998; 95(24):14196-14201.
57. Radeff-Huang J, Seasholtz TM, Chang JW, Smith JM and Walsh CT. TNF-alpha -stimulated cell proliferation is mediated through sphingosine kinase-dependent AKT activation and cyclin D expression. J Biol Chem. 2007; 282:863-70.
58. Xia P, Wang L, Moretti PA, Albanese N, Chai F, Pitson SM, D'Andrea RJ, Gamble JR and Vadas MA. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J Biol Chem. 2002; 277(10):7996-8003.
59. Xiong Y, Lee HJ, Mariko B, Lu YC, Dannenberg AJ, Haka AS, Maxfield FR, Camerer E, Proia RL and Hla T. Sphingosine kinases are not required for inflammatory responses in macrophages. J Biol Chem. 2013; 288(45):32563-32573.
60. Shida D, Fang X, Kordula T, Takabe K, Lepine S, Alvarez SE, Milstien S and Spiegel S. Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 2008; 68(16):6569-6577.
61. Hobson JP, Rosenfeldt HM, Barak LS, Olivera A, Poulton S, Caron MG, Milstien S and Spiegel S. Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science. 2001; 291(5509):1800-1803.
62. Takuwa Y. Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. Biochim Biophys Acta. 2002; 1582(1-3):112-120.
63. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB and Sabbadini RA. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006; 9(3):225-238.
64. Doll F, Pfeilschifter J and Huwiler A. Prolactin upregulates sphingosine kinase-1 expression and activity in the human breast cancer cell line MCF7 and triggers enhanced proliferation and migration. Endocr Relat Cancer. 2007; 14(2):325-335.
65. Kaneider NC, Djanani A, Fischer-Colbrie R and Wiedermann CJ. Sphingosine kinase-dependent directional migration of leukocytes in response to phorbol ester. Biochem Biophys Res Commun. 2002; 297(4):806-810.
66. Maceyka M, Alvarez SE, Milstien S and Spiegel S. Filamin A links sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. Mol Cell Biol. 2008; 28(18):5687-5697.
67. Schwalm S, Doll F, Romer I, Bubnova S, Pfeilschifter J and Huwiler A. Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochem Biophys Res Commun. 2008; 368(4):1020-1025.
68. Bergelin N, Blom T, Heikkila J, Lof C, Alam C, Balthasar S, Slotte JP, Hinkkanen A and Tornquist K. Sphingosine kinase as an oncogene: autocrine sphingosine 1-phosphate modulates ML-1 thyroid carcinoma cell migration by a mechanism dependent on protein kinase C-alpha and ERK1/2. Endocrinology. 2009; 150(5):2055-2063.
69. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res. 2003; 47(5):401-407.
70. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S and Proia RL. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000; 106(8):951-961.
71. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL and Cyster JG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004; 427(6972):355-360.
72. Paik JH, Chae S, Lee MJ, Thangada S and Hla T. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3-and beta1-containing integrins. J Biol Chem. 2001; 276(15):11830-11837.
73. Hashimoto M, Wang X, Mao L, Kobayashi T, Kawasaki S, Mori N, Toews ML, Kim HJ, Cerutis R, Liu X and Rennard SI. Sphingosine 1-phosphate Potentiates Human Lung Fibroblast Chemotaxis through the S1P2 Receptor. Am J Respir Cell Mol Biol. 2008; 39:356-63.
74. Goparaju SK, Jolly PS, Watterson KR, Bektas M, Alvarez S, Sarkar S, Mel L, Ishii I, Chun J, Milstien S and Spiegel S. The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol Cell Biol. 2005; 25(10):4237-4249.
75. Sanchez T, Thangada S, Wu MT, Kontos CD, Wu D, Wu H and Hla T. PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci U S A. 2005; 102(12):4312-4317.
76. Sugimoto N, Takuwa N, Okamoto H, Sakurada S and Takuwa Y. Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform. Mol Cell Biol. 2003; 23(5):1534-1545.
77. Bryan L, Paugh BS, Kapitonov D, Wilczynska KM, Alvarez SM, Singh SK, Milstien S, Spiegel S and Kordula T. Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinasetype plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness. Mol Cancer Res. 2008; 6(9):1469-1477.
78. Duan HF, Wu CT, Lu Y, Wang H, Liu HJ, Zhang QW, Jia XX, Lu ZZ and Wang LS. Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells. Exp Cell Res. 2004; 298(2):593-601.
79. Licht T, Tsirulnikov L, Reuveni H, Yarnitzky T and Ben-Sasson SA. Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood. 2003; 102(6):2099-2107.
80. Liu F, Verin AD, Wang P, Day R, Wersto RP, Chrest FJ, English DK and Garcia JG. Differential regulation of sphingosine-1-phosphate-and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity. Am J Respir Cell Mol Biol. 2001; 24(6):711-719.
81. Wu W, Shu X, Hovsepyan H, Mosteller RD and Broek D. VEGF receptor expression and signaling in human bladder tumors. Oncogene. 2003; 22(22):3361-3370.
82. Chae SS, Paik JH, Furneaux H and Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest. 2004; 114(8):1082-1089.
83. Anelli V, Gault CR, Snider AJ and Obeid LM. Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro. FASEB J. 2010; 24(8):2727-2738.
84. Brizuela L, Dayon A, Doumerc N, Ader I, Golzio M, Izard JC, Hara Y, Malavaud B and Cuvillier O. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. FASEB J. 2010; 24(10):3882-3894.
85. Min J, Van Veldhoven PP, Zhang L, Hanigan MH, Alexander H and Alexander S. Sphingosine-1-phosphate lyase regulates sensitivity of human cells to select chemotherapy drugs in a p38-dependent manner. Mol Cancer Res. 2005; 3(5):287-296.
86. Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissie J, Kohama T, Waxman J, Malavaud B and Cuvillier O. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther. 2008; 7(7):1836-1845.
87. Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J and Pchejetski D. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. International journal of cancer. 2009; 125:2728-36.
88. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissie J, Malavaud B, Waxman J and Cuvillier O. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010; 70(21):8651-8661.
89. Sukocheva O, Wang L, Verrier E, Vadas MA and Xia P. Restoring endocrine response in breast cancer cells by inhibition of the sphingosine kinase-1 signaling pathway. Endocrinology. 2009; 150(10):4484-4492.
90. Huwiler A, Kotelevets N, Xin C, Pastukhov O, Pfeilschifter J and Zangemeister-Wittke U. Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage. Br J Pharmacol. 2011; 162(2):532-543.
91. Jung ID, Lee JS, Kim YJ, Jeong YI, Lee CM, Baumruker T, Billlich A, Banno Y, Lee MG, Ahn SC, Park WS, Han J and Park YM. Sphingosine kinase inhibitor suppresses a Th1 polarization via the inhibition of immunostimulatory activity in murine bone marrow-derived dendritic cells. Int Immunol. 2007; 19(4):411-426.
92. Bruno AP, Laurent G, Averbeck D, Demur C, Bonnet J, Bettaieb A, Levade T and Jaffrezou JP. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell Death Differ. 1998; 5(2):172-182.
93. Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J and Weichselbaum RR. Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res. 1997; 57(7):1270-1275.
94. Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B and Spiegel S. N,N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry. 1998; 37(37):12892-12898.
95. Sweeney EA, Sakakura C, Shirahama T, Masamune A, Ohta H, Hakomori S and Igarashi Y. Sphingosine and its methylated derivative N,N-dimethylsphingosine (DMS) induce apoptosis in a variety of human cancer cell lines. Int J Cancer. 1996; 66(3):358-366.
96. Cuvillier O. Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin Ther Targets. 2008; 12(8):1009-1020.
97. Endo K, Igarashi Y, Nisar M, Zhou Q and Hakomori S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N, N-dimethyl and N, N, N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer research. 1991; 51(6):1613.
98. Okoshi H, Hakomori S, Nisar M, Zhou Q, Kimura S, Tashiro K and Igarashi Y. Cell membrane signaling as target in cancer therapy II: Inhibitory effect of N, N, N-trimethylsphingosine on metastatic potential of murine B16 melanoma cell line through blocking of tumor celldependent platelet aggregation. Cancer research. 1991; 51(22):6019.
99. Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP and Spiegel S. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res. 2000; 60(16):4468-4474.
100. Merrill AH, Jr., Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ, Riley RT, Voss KA and Wang E. Sphingolipids-the enigmatic lipid class: biochemistry, physiology, and pathophysiology. Toxicol Appl Pharmacol. 1997; 142(1):208-225.
101. Kono K, Sugiura M and Kohama T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c. J Antibiot (Tokyo). 2002; 55(1):99-103.
102. Bonhoure E, Lauret A, Barnes D, Martin C, Malavaud B, Kohama T, Melo J and Cuvillier O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia. 2008; 22(5):971-979.
103. French K, Upson J, Keller S, Zhuang Y, Yun J and Smith C. Antitumor activity of sphingosine kinase inhibitors. Journal of Pharmacology and Experimental Therapeutics. 2006; 318(2):596.
104. Tonelli F, Alossaimi M, Williamson L, Tate RJ, Watson DG, Chan E, Bittman R, Pyne NJ and Pyne S. The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism. Br J Pharmacol. 2013; 168(6):1497-1505.
105. Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S and Spiegel S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008; 112:1382-91.
106. Xiang Y, Asmussen G, Booker M, Hirth B, Kane JL, Jr., Liao J, Noson KD and Yee C. Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009; 19(21):6119-6121.
107. Kennedy AJ, Mathews TP, Kharel Y, Field SD, Moyer ML, East JE, Houck JD, Lynch KR and Macdonald TL. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells. J Med Chem. 2011; 54(10):3524-3548.
108. Tonelli F, Lim KG, Loveridge C, Long J, Pitson SM, Tigyi G, Bittman R, Pyne S and Pyne NJ. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal. 2010; 22(10):1536-1542.
109. Sharma AK. Sphingo-guanidines and their use as inhibitors of sphingosine kinase (WO2010078247). Expert Opin Ther Pat. 2011; 21(5):807-812.
110. Hengst J, Wang X, Sk U, Sharma A, Amin S and Yun J. Development of a Sphingosine Kinase 1 Specific Small-Molecule Inhibitor. Bioorganic & Medicinal Chemistry Letters. 2010; 20:7498-502.
111. Banno Y, Kato M, Hara A and Nozawa Y. Evidence for the presence of multiple forms of Sph kinase in human platelets. Biochemical Journal. 1998; 335(Pt 2):301.
112. Dickson MA, Carvajal RD, Merrill AH, Jr., Gonen M, Cane LM and Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011; 17(8):2484-2492.
113. Schnute ME, McReynolds MD, Kasten T, Yates M, Jerome G, Rains JW, Hall T, Chrencik J, Kraus M, Cronin CN, Saabye M, Highkin MK, Broadus R, Ogawa S, Cukyne K, Zawadzke LE, et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012; 444(1):79-88.
114. Kharel Y, Mathews TP, Gellett AM, Tomsig JL, Kennedy PC, Moyer ML, Macdonald TL and Lynch KR. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate. Biochem J. 2011; 440(3):345-353.
115. Rex K, Jeffries S, Brown ML, Carlson T, Coxon A, Fajardo F, Frank B, Gustin D, Kamb A, Kassner PD, Li S, Li Y, Morgenstern K, Plant M, Quon K, Ruefli-Brasse A, et al. Sphingosine kinase activity is not required for tumor cell viability. PLoS One. 2013; 8(7):e68328.
116. Lee JW, Ryu JY, Yoon G, Jeon HK, Cho YJ, Choi JJ, Song SY, Do IG, Lee YY, Kim TJ, Choi CH, Kim BG and Bae DS. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer. Int J Cancer. 2015; 137(1):221-229.
117. Datta A, Loo SY, Huang B, Wong L, Tan SS, Tan TZ, Lee SC, Thiery JP, Lim YC, Yong WP, Lam Y, Kumar AP and Yap CT. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. Oncotarget. 2014; 5(15):5920-5933. doi 10.18632/oncotarget.1874.
118. Martin JL, de Silva HC, Lin MZ, Scott CD and Baxter RC. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triplenegative breast cancer cells to EGF receptor blockade. Molecular cancer therapeutics. 2014; 13(2):316-328.
119. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B and Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer research. 2005; 65(24):11667-11675.
120. Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, Chiba K, Hoshino Y and Okumoto T. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. The Journal of antibiotics. 1994; 47(2):208-215.
121. Chiba K, Yanagawa Y, Masubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M and Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. Journal of immunology. 1998; 160(10):5037-5044.
122. Lim KG, Tonelli F, Li Z, Lu X, Bittman R, Pyne S and Pyne NJ. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J Biol Chem. 2011; 286(21):18633-18640.
123. Vessey DA, Kelley M, Zhang J, Li L, Tao R and Karliner JS. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J Biochem Mol Toxicol. 2007; 21(5):273-279.
124. Kharel Y, Lee S, Snyder AH, Sheasley-O'Neill SL, Morris MA, Setiady Y, Zhu R, Zigler MA, Burcin TL, Ley K, Tung KS, Engelhard VH, Macdonald TL, Pearson-White S and Lynch KR. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. The Journal of biological chemistry. 2005; 280(44):36865-36872.
125. Paugh SW, Payne SG, Barbour SE, Milstien S and Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS letters. 2003; 554(1-2):189-193.
126. Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N and Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. The Journal of biological chemistry. 2003; 278(48):47408-47415.
127. Sanchez T, Estrada-Hernandez T, Paik JH, Wu MT, Venkataraman K, Brinkmann V, Claffey K and Hla T. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factorinduced vascular permeability. J Biol Chem. 2003; 278(47):47281-47290.
128. Hogenauer K, Billich A, Pally C, Streiff M, Wagner T, Welzenbach K and Nussbaumer P. Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues. ChemMedChem. 2008; 3(7):1027-1029.
129. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, Wei SH, Parker I, Jo E, Cheng WC, Cahalan MD, Wong CH and Rosen H. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol. 2006; 2(8):434-441.
130. Budde K, Schutz M, Glander P, Peters H, Waiser J, Liefeldt L, Neumayer HH and Bohler T. FTY720 (fingolimod) in renal transplantation. Clin Transplant. 2006; 20 Suppl 17:17-24.
131. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol Ther. 2005; 108(3):308-319.
132. Jo E, Sanna MG, Gonzalez-Cabrera PJ, Thangada S, Tigyi G, Osborne DA, Hla T, Parrill AL and Rosen H. S1P1-selective in vivo-active agonists from highthroughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol. 2005; 12(6):703-715.
133. Lo CG, Xu Y, Proia RL and Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J Exp Med. 2005; 201(2):291-301.
134. Hla T and Brinkmann V. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology. 2011; 76(8 Suppl 3):S3-8.
135. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL and Kappos L. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008; 71(16):1261-1267.
136. Strader CR, Pearce CJ and Oberlies NH. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. Journal of natural products. 2011; 74(4):900-907.
137. Egom EE, Ke Y, Musa H, Mohamed TM, Wang T, Cartwright E, Solaro RJ and Lei M. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. Journal of molecular and cellular cardiology. 2010; 48(2):406-414.
138. Egom EE, Mohamed TM, Mamas MA, Shi Y, Liu W, Chirico D, Stringer SE, Ke Y, Shaheen M, Wang T, Chacko S, Wang X, Solaro RJ, Fath-Ordoubadi F, Cartwright EJ and Lei M. Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. American journal of physiology Heart and circulatory physiology. 2011; 301(4):H1487-1495.
139. Jin ZQ, Goetzl EJ and Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation. 2004; 110(14):1980-1989.
140. Pchejetski D, Kunduzova O, Dayon A, Calise D, Seguelas MH, Leducq N, Seif I, Parini A and Cuvillier O. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res. 2007; 100(1):41-49.
141. Skerjanec A, Tedesco H, Neumayer HH, Cole E, Budde K, Hsu CH and Schmouder R. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J Clin Pharmacol. 2005; 45(11):1268-1278.
142. Braun WE. Renal transplantation: basic concepts and evolution of therapy. Journal of clinical apheresis. 2003; 18(3):141-152.
143. Suzuki S, Li XK, Enosawa S and Shinomiya T. A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology. 1996; 89(4):518-523.
144. Nagahara Y, Enosawa S, Ikekita M, Suzuki S and Shinomiya T. Evidence that FTY720 induces T cell apoptosis in vivo. Immunopharmacology. 2000; 48(1):75-85.
145. Yoshino T, Tabunoki H, Sugiyama S, Ishii K, Kim SU and Satoh J. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2. Cellular and molecular neurobiology. 2011; 31(7):1009-1020.
146. Chua CW, Lee DT, Ling MT, Zhou C, Man K, Ho J, Chan FL, Wang X and Wong YC. FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer. Int J Cancer. 2005; 117(6):1039-1048.
147. Permpongkosol S, Wang JD, Takahara S, Matsumiya K, Nonomura N, Nishimura K, Tsujimura A, Kongkanand A and Okuyama A. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis. Int J Cancer. 2002; 98(2):167-172.
148. Wang JD, Takahara S, Nonomura N, Ichimaru N, Toki K, Azuma H, Matsumiya K, Okuyama A and Suzuki S. Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate. 1999; 40(1):50-55.
149. Zhou C, Ling MT, Kin-Wah Lee T, Man K, Wang X and Wong YC. FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase. Cancer Lett. 2006; 233(1):36-47.
150. Azuma H, Takahara S, Ichimaru N, Wang JD, Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M, Ishihara T, Nonomura N, Suzuki S, Okuyama A and Katsuoka Y. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res. 2002; 62(5):1410-1419.
151. Nagaoka Y, Otsuki K, Fujita T and Uesato S. Effects of phosphorylation of immunomodulatory agent FTY720 (fingolimod) on antiproliferative activity against breast and colon cancer cells. Biol Pharm Bull. 2008; 31(6):1177-1181.
152. Li D, Zhang Y, Hu X, Cao W and Huang W. Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937. Journal of Huazhong University of Science and Technology Medical sciences. 2004; 24(1):45-47.
153. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, Lehman A, Perrotti D, Chen CS, Dalton JT, Muthusamy N and Byrd JC. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 2008; 111(1):275-284.
154. Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA and Muthusamy N. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res. 2010; 16(12):3182-3192.
155. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of clinical investigation. 2007; 117(9):2408-2421.
156. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, Sim AT, Ashman LK and Verrills NM. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res. 2010; 70(13):5438-5447.
157. Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, et al. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005; 65(16):7478-7484.
158. Fujino M, Li XK, Kitazawa Y, Guo L, Kawasaki M, Funeshima N, Amano T and Suzuki S. Distinct pathways of apoptosis triggered by FTY720, etoposide, and anti-Fas antibody in human T-lymphoma cell line (Jurkat cells). The Journal of pharmacology and experimental therapeutics. 2002; 300(3):939-945.
159. Nagahara Y, Ikekita M and Shinomiya T. Immunosuppressant FTY720 induces apoptosis by direct induction of permeability transition and release of cytochrome c from mitochondria. J Immunol. 2000; 165(6):3250-3259.
160. Lucas da Silva LB, Ribeiro DA, Cury PM, Cordeiro JA and Bueno V. FTY720 treatment in experimentally urethaneinduced lung tumors. J Exp Ther Oncol. 2008; 7(1):9-15.
161. Salinas NR, Lopes CT, Palma PV, Oshima CT and Bueno V. Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720. Pathol Oncol Res. 2009; 15(4):549-554.
162. Salinas NR, Oshima CT, Cury PM, Cordeiro JA and Bueno V. FTY720 and lung tumor development. International immunopharmacology. 2009; 9(6):689-693.
163. Ng KT, Man K, Ho JW, Sun CK, Lee TK, Zhao Y, Lo CM, Poon RT and Fan ST. Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. Int J Oncol. 2007; 30(2):375-380.
164. Ho JW, Man K, Sun CK, Lee TK, Poon RT and Fan ST. Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther. 2005; 4(9):1430-1438.
165. Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R and Fan ST. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis. 2004; 25(12):2397-2405.
166. Lee TK, Man K, Ho JW, Wang XH, Poon RT, Xu Y, Ng KT, Chu AC, Sun CK, Ng IO, Sun HC, Tang ZY, Xu R and Fan ST. FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma. Clin Cancer Res. 2005; 11(23):8458-8466.
167. Shen Y, Cai M, Xia W, Liu J, Zhang Q, Xie H, Wang C, Wang X and Zheng S. FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells. Cancer Lett. 2007; 254(2):288-297.
168. Shen Y, Wang X, Xia W, Wang C, Cai M, Xie H, Zhou L and Zheng S. Antiproliferative and overadditive effects of rapamycin and FTY720 in pancreatic cancer cells in vitro. Transplant Proc. 2008; 40(5):1727-1733.
169. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y and Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 2003; 169(6):2372-2377.
170. Ubai T, Azuma H, Kotake Y, Inamoto T, Takahara K, Ito Y, Kiyama S, Sakamoto T, Horie S, Muto S, Takahara S, Otsuki Y and Katsuoka Y. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res. 2007; 27(1A):75-88.
171. Lee WJ, Yoo HS, Suh PG, Oh S, Lim JS and Lee YM. Sphingosine mediates FTY720-induced apoptosis in LLCPK1 cells. Experimental & molecular medicine. 2004; 36(5):420-427.
172. Sonoda Y, Yamamoto D, Sakurai S, Hasegawa M, Aizu-Yokota E, Momoi T and Kasahara T. FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochemical and biophysical research communications. 2001; 281(2):282-288.
173. Zheng T, Meng X, Wang J, Chen X, Yin D, Liang Y, Song X, Pan S, Jiang H and Liu L. PTEN-and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. Journal of cellular biochemistry. 2010; 111(1):218-228.
174. Xing Y, Wang ZH, Ma DH and Han Y. FTY720 enhances chemosensitivity of colon cancer cells to doxorubicin and etoposide via the modulation of P-glycoprotein and multidrug resistance protein 1. Journal of digestive diseases. 2014; 15(5):246-259.
175. Zhang N, Qi Y, Wadham C, Wang L, Warren A, Di W and Xia P. FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy. Autophagy. 2010; 6(8):1157-1167.
176. Cristobal I, Manso R, Rincon R, Carames C, Senin C, Borrero A, Martinez-Useros J, Rodriguez M, Zazo S, Aguilera O, Madoz-Gurpide J, Rojo F and Garcia-Foncillas J. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Molecular cancer therapeutics. 2014; 13(4):938-947.
177. Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfe G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clinical cancer research. 2013; 19(1):138-147.
178. Marcus A and Eshhar Z. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert opinion on biological therapy. 2014; 14(7):947-954.
179. LaMontagne K, Littlewood-Evans A, Schnell C, O'Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liau G, Billy E, Theuer A, Hla T and Wood J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006; 66(1):221-231.
180. Zhang L, Wang H, Zhu J, Ding K and Xu J. FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumour biology. 2014; 35:10707-14.
181. Wolf AM, Eller K, Zeiser R, Durr C, Gerlach UV, Sixt M, Markut L, Gastl G, Rosenkranz AR and Wolf D. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol. 2009; 183(6):3751-3760.
182. Nishikawa H and Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer. 2010; 127(4):759-767.
183. Domhan S, Zeier M and Abdollahi A. Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant. 2009; 24(4):1097-1103.
184. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, Takabe K, Kordula T, Milstien S and Spiegel S. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitisassociated cancer. Cancer cell. 2013; 23(1):107-120.
185. Nagahashi M, Hait NC, Maceyka M, Avni D, Takabe K, Milstien S and Spiegel S. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Advances in biological regulation. 2014; 54:112-120.
186. Loveridge C, Tonelli F, Leclercq T, Lim KG, Long JS, Berdyshev E, Tate RJ, Natarajan V, Pitson SM, Pyne NJ and Pyne S. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J Biol Chem. 2010; 285(50):38841-38852.
187. Ren S, Xin C, Pfeilschifter J and Huwiler A. A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation. Cell Physiol Biochem. 2010; 26(1):97-104.
188. Ishitsuka A, Fujine E, Mizutani Y, Tawada C, Kanoh H, Banno Y and Seishima M. FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression. Int J Mol Med. 2014; 34(4):1169-1174.
189. Perrotti D and Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer metastasis reviews. 2008; 27(2):159-168.
190. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer cell. 2005; 8(5):355-368.
191. Westermarck J and Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends in molecular medicine. 2008; 14(4):152-160.
192. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ and Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011; 25(4):606-614.
193. Baldacchino S, Saliba C, Petroni V, Fenech AG, Borg N and Grech G. Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720. The EPMA journal. 2014; 5(1):3.
194. Perrotti D and Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013; 14(6):e229-238.
195. Kalla C, Scheuermann MO, Kube I, Schlotter M, Mertens D, Dohner H, Stilgenbauer S and Lichter P. Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. Eur J Cancer. 2007; 43(8):1328-1335.
196. Matsuoka Y, Nagahara Y, Ikekita M and Shinomiya T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. British journal of pharmacology. 2003; 138(7):1303-1312.
197. Dobrowsky RT, Kamibayashi C, Mumby MC and Hannun YA. Ceramide activates heterotrimeric protein phosphatase 2A. The Journal of biological chemistry. 1993; 268(21):15523-15530.
198. Suzuki E, Handa K, Toledo MS and Hakomori S. Sphingosine-dependent apoptosis: a unified concept based on multiple mechanisms operating in concert. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(41):14788-14793.
199. Ruvolo PP, Clark W, Mumby M, Gao F and May WS. A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function. The Journal of biological chemistry. 2002; 277(25):22847-22852.
200. Ruvolo PP, Deng X, Ito T, Carr BK and May WS. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. The Journal of biological chemistry. 1999; 274(29):20296-20300.
201. Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA and Ogretmen B. Direct interaction between the inhibitor 2 and ceramide via sphingolipidprotein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 2009; 23(3):751-763.
202. Habrukowich C, Han DK, Le A, Rezaul K, Pan W, Ghosh M, Li Z, Dodge-Kafka K, Jiang X, Bittman R and Hla T. Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. The Journal of biological chemistry. 2010; 285(35):26825-26831.
203. Liu H, Gu Y, Yin J, Zheng G, Wang C, Zhang Z, Deng M, Liu J, Jia X and He Z. SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. Cellular signalling. 2014; 26(12):2710-2720.
204. Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N, Jr., Konopleva M, Calin G, Kornblau SM, et al. The protein phosphatase 2A regulatory subunit B55alpha is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochimica et biophysica acta. 2014; 1843(9):1969-1977.
205. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of clinical investigation. 2013; 123(10):4144-4157.
206. Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, et al. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia. Leukemia. 2014.
207. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, et al. Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013; 122(11):1923-1934.
208. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ, Selvam SP, Senkal CE, Garrett-Mayer E, De Palma RM, Fedarovich D, Liu A, Habib AA, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO molecular medicine. 2013; 5(1):105-121.
209. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M and Lynch KR. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. The Journal of biological chemistry. 2002; 277(24):21453-21457.
210. Ushitora Y, Tashiro H, Ogawa T, Tanimoto Y, Kuroda S, Kobayashi T, Miyata Y, Itamoto T, Asahara T and Ohdan H. Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog. Transplantation. 2009; 88(8):980-986.
211. Kluk MJ, Ryan KP, Wang B, Zhang G, Rodig SJ and Sanchez T. Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration. Laboratory investigation. 2013; 93(4):462-471.
212. Nam SW, Clair T, Campo CK, Lee HY, Liotta LA and Stracke ML. Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of rastransformed cells. Oncogene. 2000; 19(2):241-247.
213. Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA and Stracke ML. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer research. 2001; 61(18):6938-6944.
214. Lee HY, Bae GU, Jung ID, Lee JS, Kim YK, Noh SH, Stracke ML, Park CG, Lee HW and Han JW. Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells. FEBS letters. 2002; 515(1-3):137-140.
215. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J and Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. The Journal of cell biology. 2002; 158(2):227-233.
216. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, Min SK, Han JW, Lee HW and Lee HY. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clinical & experimental metastasis. 2002; 19(7):603-608.
217. Gijsbers R, Aoki J, Arai H and Bollen M. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS letters. 2003; 538(1-3):60-64.
218. Koh E, Clair T, Woodhouse EC, Schiffmann E, Liotta L and Stracke M. Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities. Cancer research. 2003; 63(9):2042-2045.
219. van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR and Moolenaar WH. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasisenhancing and angiogenic lysophospholipase D. Cancer letters. 2008; 266(2):203-208.
220. Matsumura M, Tsuchida M, Isoyama N, Takai K and Matsuyama H. FTY720 mediates cytochrome c release from mitochondria during rat thymocyte apoptosis. Transplant immunology. 2010; 23(4):174-179.
221. Kiyota M, Kuroda J, Yamamoto-Sugitani M, Shimura Y, Nakayama R, Nagoshi H, Mizutani S, Chinen Y, Sasaki N, Sakamoto N, Kobayashi T, Matsumoto Y, Horiike S and Taniwaki M. FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. Apoptosis. 2013; 18(11):1437-1446.
222. Nagahara Y, Ikekita M and Shinomiya T. T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. British journal of pharmacology. 2002; 137(7):953-962.
223. Azuma H, Horie S, Muto S, Otsuki Y, Matsumoto K, Morimoto J, Gotoh R, Okuyama A, Suzuki S, Katsuoka Y and Takahara S. Selective cancer cell apoptosis induced by FTY720; evidence for a Bcl-dependent pathway and impairment in ERK activity. Anticancer Res. 2003; 23(4):3183-3193.
224. Marvaso G, Barone A, Amodio N, Raimondi L, Agosti V, Altomare E, Scotti V, Lombardi A, Bianco R, Bianco C, Caraglia M, Tassone P and Tagliaferri P. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. Cancer Biol Ther. 2014; 15(6):797-805.
225. Li MH, Hla T and Ferrer F. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatric blood & cancer. 2013; 60(9):1418-1423.
226. Woodcock JM, Ma Y, Coolen C, Pham D, Jones C, Lopez AF and Pitson SM. Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cellular signalling. 2010; 22(9):1291-1299.
227. Ma Y, Pitson S, Hercus T, Murphy J, Lopez A and Woodcock J. Sphingosine activates protein kinase A type II by a novel cAMP-independent mechanism. The Journal of biological chemistry. 2005; 280(28):26011-26017.
228. Hamaguchi A, Suzuki E, Murayama K, Fujimura T, Hikita T, Iwabuchi K, Handa K, Withers DA, Masters SC, Fu H and Hakomori S. Sphingosine-dependent protein kinase-1, directed to 14-3-3, is identified as the kinase domain of protein kinase C delta. The Journal of biological chemistry. 2003; 278(42):41557-41565.
229. Cristobal I, Gonzalez-Alonso P, Daoud L, Solano E, Torrejon B, Manso R, Madoz-Gurpide J, Rojo F and Garcia-Foncillas J. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer. Mar Drugs. 2015; 13(6):3276-3286.
230. Zhang X, Goncalves R and Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol. 2008; Chapter 14:Unit 14 11.
231. Fransson R, McCracken AN, Chen B, McMonigle RJ, Edinger AL and Hanessian S. Design, Synthesis, and Antileukemic Activity of Stereochemically Defined Constrained Analogs of FTY720 (Gilenya). ACS medicinal chemistry letters. 2013; 4(10).
232. Li YC, Liu ZG, Yao K, Wang HH, Hu R, Yang W and Liao AJ. [Mechanisms of ROS in U266 cell death induced by FTY720]. Chinese Association of Pathophysiology. 2013; 21(3):643-646.
233. Zhang N, Dai L, Qi Y, Di W and Xia P. Combination of FTY720 with cisplatin exhibits antagonistic effects in ovarian cancer cells: role of autophagy. International journal of oncology. 2013; 42(6):2053-2059.
234. Pereira FV, Arruda DC, Figueiredo CR, Massaoka MH, Matsuo AL, Bueno V and Rodrigues EG. FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Clinics. 2013; 68(7):1018-1027.
235. Lu Z, Wang J, Zheng T, Liang Y, Yin D, Song R, Pei T, Pan S, Jiang H and Liu L. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling. BMC Cancer. 2014; 14:783.
236. Zhang L, Wang H, Zhu J, Ding K and Xu J. FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumour Biol. 2014; 35(11):10707-10714.
237. Marvaso G, Barone A, Amodio N, Raimondi L, Agosti V, Altomare E, Scotti V, Lombardi A, Bianco R, Bianco C, Caraglia M, Tassone P and Tagliaferri P. Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. Cancer biology & therapy. 2014; 15(6):797-805.
238. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):402-415.
239. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L and Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5):387-401.
240. Onishi H, Kiyota A, Koya N, Tanaka H, Umebayashi M, Katano M and Morisaki T. Random migration contributes to cytotoxicity of activated CD8+ T-lymphocytes but not NK cells. Anticancer research. 2014; 34(8):3947-3956.
241. Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK and Chen CS. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology. 2011; 53(6):1943-1958.
242. Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N and Phelps MA. Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis. 2014; 98:160-165.
243. Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ and Muthusamy N. A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery. Nanomedicine. 2014; 10(2):393-400.
244. Yu B, Mao Y, Yuan Y, Yue C, Wang X, Mo X, Jarjoura D, Paulaitis ME, Lee RJ, Byrd JC, Lee LJ and Muthusamy N. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials. 2013; 34(26):6185-6193.
245. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R and Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. Journal for immunotherapy of cancer. 2014; 2:3.
246. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G and Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006; 355(11):1124-1140.
247. Buddaseth S, Gottmann W, Blasczyk R and Huyton T. Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod). Cancer Biol Ther. 2014; 15(3):289-296.
248. Pchejetski D, Bohler T, Stebbing J and Waxman J. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol. 2011; 8(10):569-678.
249. Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Bohler T and Pchejetski D. Therapeutic potential of targeting SK1 in human cancers. Adv Cancer Res. 2013; 117:143-200.
250. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci. 2011; 36(2):97-107.